Human Anti-GPA33 Antibody for Intestine-Targeted IBD Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There are no effective therapeutic agents for inflammatory bowel disease that can selectively deliver drugs to intestinal tissues without causing systemic immune suppression and side effects, and existing anti-GPA33 antibodies are not targeted for intestinal diseases other than cancer.
Innovation Solution
Development of a human antibody that specifically binds to both human and mouse GPA33, allowing for intestine-specific migration and accumulation, and conjugation with functional molecules to promote Wnt/β-catenin signaling for treating inflammatory bowel disease.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-specific immunosuppressants (corticosteroids, thiopurine preparations, calcineurin inhibitors) are used to treat inflammatory bowel disease, then the disease can be suppressed, but systemic immune function is reduced and infectious diseases occur as side effects
Solution Approach 1:
The patent applies local quality by designing an antibody that specifically targets GPA33 expressed in intestinal tissues, delivering therapeutic effect locally to the intestine rather than systemically. The antibody-drug conjugate accumulates selectively in intestinal tissues through binding to GPA33, providing localized immunosuppression without affecting systemic immune function, thus resolving the contradiction between disease suppression efficacy and harmful systemic side effects
Solution Approach 2:
The patent uses an anti-GPA33 antibody as an intermediary carrier to deliver therapeutic agents specifically to intestinal tissues. The antibody acts as a mediator that binds to GPA33 on intestinal cells and delivers the attached therapeutic molecule (such as a cytotoxic agent or immunomodulator) directly to the target tissue, avoiding systemic distribution and reducing harmful side effects while maintaining effective disease suppression
2Reliability
If existing anti-GPA33 antibodies are used for cancer treatment, then tumor cells expressing GPA33 can be targeted, but there are no reports of their use for intestinal diseases other than cancer
Solution Approach 1:
The patent applies universality by demonstrating that the anti-GPA33 antibody can serve multiple functions beyond cancer treatment. The same antibody that recognizes GPA33 on tumor cells is shown to effectively target intestinal tissues in inflammatory bowel disease, indicating the antibody's versatility across different intestinal pathologies. This multi-functional application resolves the contradiction between specific target recognition and limited application scope
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention provides a human antibody or an antigen-binding portion thereof that specifically binds to human GPA33 and mouse GPA33.